Sydney School of Public Health, University of Sydney, Sydney, New South Wales, Australia.
School of Mathematics and Applied Statistics, University of Wollongong, Wollongong, New South Wales, Australia.
BMJ Open. 2019 Feb 22;9(2):e026263. doi: 10.1136/bmjopen-2018-026263.
People with end-stage kidney disease (ESKD) have up to 30-fold higher risk of stroke than the general population.
To determine risk factors associated with stroke death in the ESKD population.
We identified all patients with incident ESKD in Australia (1980-2013) and New Zealand (1988-2012) from the Australian and New Zealand Dialysis and Transplant Registry (ANZDATA) registry. We ascertained underlying cause of death from data linkage with national death registries and risk factors from ANZDATA. Using a competing risks multivariable regression model, we estimated cumulative incidence of stroke and non-stroke deaths, and risk factors for stroke deaths (adjusted sub-HR, SHR).
We included 60 823 people with ESKD. There were 941 stroke deaths and 33 377 non-stroke deaths during 381 874 person-years of follow-up. Overall, the cumulative incidence of stroke death was 0.9% and non-stroke death was 36.8% 5 years after starting ESKD treatment. The risk of stroke death was higher at older ages (SHR 1.92, 95% CI 1.45 to 2.55), in females (SHR 1.41, 95% CI 1.21 to 1.64), in people with cerebrovascular disease (SHR 2.39, 95% CI 1.99 to 2.87), with ESKD caused by hypertensive/renovascular disease (SHR 1.39, 95% CI 1.09 to 1.78) or polycystic kidney disease (SHR 1.38, 95% CI 1.00 to 1.90), with earlier year of ESKD treatment initiation (SHR 1.93, 95% CI 1.56 to 2.39) and receiving dialysis (transplant vs haemodialysis SHR 0.27, 95% CI 0.09 to 0.84).
Patients with ESKD with higher risk of stroke death are older, women, with cerebrovascular disease, with hypertensive/renovascular or polycystic kidney disease cause of ESKD, with earlier year of ESKD treatment and receiving dialysis. These groups may benefit from targeted stroke prevention interventions.
终末期肾病(ESKD)患者的中风风险比一般人群高 30 倍。
确定 ESKD 人群中风死亡的相关危险因素。
我们从澳大利亚和新西兰透析和移植登记处(ANZDATA)登记处确定了澳大利亚(1980-2013 年)和新西兰(1988-2012 年)所有新发 ESKD 患者。我们通过与国家死亡登记处的数据链接确定了根本死因,并从 ANZDATA 中确定了危险因素。使用竞争风险多变量回归模型,我们估计了中风和非中风死亡的累积发生率,以及中风死亡的危险因素(调整后的亚危险比[SHR])。
我们纳入了 60823 名 ESKD 患者。在 381874 人年的随访中,有 941 例中风死亡和 33377 例非中风死亡。总体而言,中风死亡的累积发生率为 0.9%,ESKD 治疗后 5 年非中风死亡的累积发生率为 36.8%。年龄较大(SHR 1.92,95%CI 1.45 至 2.55)、女性(SHR 1.41,95%CI 1.21 至 1.64)、脑血管疾病(SHR 2.39,95%CI 1.99 至 2.87)、高血压/肾血管疾病(SHR 1.39,95%CI 1.09 至 1.78)或多囊肾病(SHR 1.38,95%CI 1.00 至 1.90)引起的 ESKD、ESKD 治疗起始较早(SHR 1.93,95%CI 1.56 至 2.39)和接受透析(移植与血液透析 SHR 0.27,95%CI 0.09 至 0.84)的患者,中风死亡风险较高。
中风死亡风险较高的 ESKD 患者年龄较大、为女性、患有脑血管疾病、患有高血压/肾血管疾病或多囊肾病引起的 ESKD、ESKD 治疗起始时间较早且接受透析。这些患者可能受益于有针对性的中风预防干预措施。